Sean Salmon Named EVP & President Cardiovascular Portfolio; Continues as EVP & President Diabetes Operating Unit

- Medtronic plc (NYSE:MDT) announced today that Sean Salmon Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1 . Salmon will also continue to lead the Diabetes Operating Unit and continue to serve on the company's Executive Committee. He succeeds Mike Coyle who will leave Medtronic effective December 31 to accept a CEO role of a publicly traded company.

"We owe Mike a debt of gratitude for his significant contributions to Medtronic," said Geoff Martha , Medtronic Chairman and Chief Executive Officer. "He's played a vital role in our Cardiovascular portfolio, including overseeing the development and launches of numerous disruptive and life-saving technologies. On behalf of the Board, I would like to thank Mike for his leadership and wish him every success."

"With 17 years leading several Medtronic business units, Sean is a highly respected leader both inside and outside of the company, with a proven track record of building and leading high-performing teams. I am confident in his ability to continue the turnaround of our Diabetes business, while ensuring continued growth and therapy adoption in our Cardiovascular portfolio," said Martha.

Salmon joined Medtronic in 2004 and spent 15 years in increasingly senior management roles within Cardiovascular, including leading the Coronary and Renal Denervation, Peripheral, Cardiac Surgery, and Structural Heart businesses, before being named the leader of Medtronic Diabetes and a member of the Medtronic Executive Committee in 2019. While in Cardiovascular, he led Medtronic to leadership in drug-eluting stents, commercialized multiple product innovations in transcatheter aortic valve replacement (TAVR), and revitalized Medtronic's renal denervation clinical program.

Salmon will continue his role leading the Diabetes turnaround and his role working closely with the other portfolio leaders and members of the Executive Committee on enterprise-level strategy and value creation under Medtronic's new operating model. With his new additional Cardiovascular responsibilities, Salmon will oversee the Cardiovascular operating units, ensuring appropriate capital allocation to optimize Medtronic's growth and profitability, overall business performance, and innovation designed to drive continued market expansion and increased share.

"I want to thank Geoff and the Board for this opportunity, which allows me to have an even greater impact on improving more patients' lives," said Salmon. "Over the past year, we've taken a number of bold steps to improve our Diabetes performance and competitiveness, including the appointment of a new leadership team, accelerating R&D investment, entering the smart pen market, and making significant progress on our customer-centric pipeline of products and services. Completing the turnaround in Diabetes remains a high priority for me. And, I'm excited to reunite and work with the exceptionally talented leaders of our Cardiovascular operating units as we continue the momentum behind Mike's vision of growth and innovation to deliver meaningful and life-enhancing cardiovascular technologies."

About Medtronic  
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:




Marguerite Copel

Ryan Weispfenning

Public Relations

Investor Relations

+1-203-214-8243

+1-763-505-4626

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/sean-salmon-named-evp--president-cardiovascular-portfolio-continues-as-evp--president-diabetes-operating-unit-301192350.html

SOURCE Medtronic plc

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/December2020/14/c7051.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Star Jones , award winning television personality & women's heart health advocate,   helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S. many women are still unaware of the risk and the importance of heart health.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×